Viral load suppression at baseline
immune-compromised, viremia
VIREMIA
The overall VL suppression at baseline was 80%, and among CALWH tested with the Roche assay, 18% had low-level viremia (VL>20 and <1000 copies/ml). Interestingly, a significant difference was observed between baseline VL suppression and site of HIV care: significantly more participants enrolled at ROS (85%) were suppressed compared to participants from the CCH (76%) (p = 0.018). Children and adolescents on PI-based second-line regimens were less likely to be suppressed compared to those on NNRTI-based first-line regimens (73% vs 84%, respectively, p = 0.006). In addition, immune-compromised children and adolescents (CD4 <200 cells/μL) were less likely to be suppressed compared to those with a CD4 of greater than 200 cells/μL (p = 0.001).